Skip to the page

Data / Form D filings / Hillhurst Biopharmaceuticals, Inc.

Hillhurst Biopharmaceuticals, Inc.: Form D filing

Hillhurst Biopharmaceuticals, Inc., a biotechnology company in Montrose, CA, filed a Form D with the SEC in 2023. The latest, on September 26, 2023, reports $1.8 million sold of a $1.8 million offering to 10 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
2029 VERDUGO BOULEVARD, #125, Montrose, CA, 91020
Phone
(818) 445-5890
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1994336

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Sep 26, 2023New notice$1,837,500$1,837,50010Sep 11, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Jeff FriedmanDirector
Andrew GompertsExecutive Officer, Director
Edward GompertsExecutive Officer, Director

Other biotechnology companies in California that filed recently

Every Form D from the week of Sep 25, 2023 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Hillhurst Biopharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.